The Salk Institute For Biological Studies. San Diego. California

The Salk Institute For Biological Studies, a San Diego-based independent nonprofit corporation conducting basic biomedical research, is a recipient of federal grants (not a federal contractor or subcontractor) and operates primarily as a prime grantee across 49 federal agencies in the National Institutes of Health, NASA, NSF, and defense research programs. The Institute does not hold federal contract prime positions or parent vehicles; its federal footprint consists entirely of research grants and cooperative agreements under which it acts as the lead recipient organization.

The Salk Institute's research portfolio spans five core programs: cancer biology, immunology and microbial pathogenesis, aging and regenerative medicine, neuroscience and neurological disorders, and plant biology. Its recent federal grant activity emphasizes investigator-initiated biomedical research funded through NIH mechanisms—primarily R01 Project Grants, R21/R33 exploratory awards, U01 cooperative agreements, and UM1 consortium grants. Representative recent work includes a $7.620 million ARPA-H cooperative agreement (Department of Interior, 2026) to develop sonogenetic platform technology for ultrasound-based therapeutic delivery; a $2.642 million NIH Office of the Director Pioneer Award (2025) investigating cortical traveling waves in long-term working memory; a $1.855 million NIAID grant (2026) on ROR-gamma-t transcriptional regulation in chromatin; and a $1.359 million NIA award (2026) characterizing activity-dependent neuronal populations in somatosensory circuits during aging. The Institute also received a $1.2 million NIGMS infrastructure grant (2025) for a high-resolution tribrid mass spectrometer and multiple NSF awards for tool development (cryo-EM, computational neuroscience, engineering).

Federal customer concentration is heavily weighted toward NIH, particularly the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the National Cancer Institute, which together account for approximately 59% of award volume by count. NIH awards (all institutes and centers combined) comprise 195 of the 684 documented awards. The Institute has also engaged with ARPA-H (health research), NASA (spaceflight physiology), NSF (biological infrastructure and STEM education), and Department of Defense research programs (Defense Health Agency, Air Force Research Laboratory). By dollar potential value, the top customer is NASA's Shared Services Center, reflecting smaller but strategically significant grants in space-relevant research. The Institute's grant activity has grown substantially—from 23 awards in 2023 to 51 in 2024—with 42 awards approaching completion in the next 24 months, indicating significant recompete exposure.

The Salk Institute maintains an extensive subgrant ecosystem, issuing 93 sub-awards to partner organizations including Scripps Research Institute, the University of California at San Diego, Brown University, Northeastern University, Northwestern University, the Rockefeller University, MIT, and numerous others. Sub-recipients perform specialized functions: structural biology and cryo-EM (Scripps, Seattle Children's Hospital), lipidomics and microprotein identification (Rockefeller), iPSC-derived neuronal modeling (Brown), computational analysis and statistical genetics (UC San Diego), and biochemical characterization. The Institute has also received federal sub-awards from prime grantees including NIH-funded collaborations on Alzheimer's disease mechanisms, HIV integration, and metabolic disease pathways.

No set-aside categories, SBA designations, or small-business provisions apply to the Salk Institute, which operates as a research-focused nonprofit independent of federal contracting vehicles. All federal funding flows through direct grant awards from grantor agencies to the Institute as a prime recipient, with typical award periods of three to five years for basic research and one to two years for exploratory or pilot work. The Institute's federal grant portfolio is characterized by high concentration in fundamental life-sciences research, particularly neurobiology, cancer genetics, immunology, and aging biology, with minimal exposure to applied development or commercialization vehicles.